Ever Supreme Bio Technology Co., Ltd. (6712) Stock Price & Analysis
6712 Stock Chart & Stats
- Day’s Range
- TWD 138.00 - TWD 146.50
- 52-Week Range
- TWD 120.95 - TWD 184.00
- Previous Close
- TWD 146.00
- Volume
- N/A
- Average Volume (3M)
- 197.41K
- Market Cap
- TWD 14.52B
- Enterprise Value
- TWD 15.26B
- Total Cash (Recent Filing)
- TWD 1.06B
- Total Debt (Recent Filing)
- TWD 232.54M
- Price to Earnings (P/E)
- 28.8
- Beta
- 0.40
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Apr 16, 2026
- Dividend Yield
- 2.20%
6712 FAQ
What was Ever Supreme Bio Technology Co., Ltd.’s price range in the past 12 months?
What is Ever Supreme Bio Technology Co., Ltd.’s market cap?
When is Ever Supreme Bio Technology Co., Ltd.’s upcoming earnings report date?
How were Ever Supreme Bio Technology Co., Ltd.’s earnings last quarter?
Is Ever Supreme Bio Technology Co., Ltd. overvalued?
Does Ever Supreme Bio Technology Co., Ltd. pay dividends?
What is Ever Supreme Bio Technology Co., Ltd.’s EPS estimate?
How many shares outstanding does Ever Supreme Bio Technology Co., Ltd. have?
What happened to Ever Supreme Bio Technology Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ever Supreme Bio Technology Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ever Supreme Bio Technology Co., Ltd.
This enterprise is dedicated to the investigation, advancement, and creation of pharmaceutical treatments leveraging human mesenchymal stem cells and immune cells. Its current portfolio features UMC01, a drug candidate undergoing Phase I clinical evaluation for addressing conditions such as myocardial infarction and stroke. Additionally, ADCV01 is progressing through Phase II clinical trials as a potential therapy for aggressive brain tumors. The company also develops CAR001, an innovative chimeric antigen receptor immune cell product, alongside bone-marrow stem cells (BMSC) used in managing chronic stroke, severe osteoarthritis, and spinal cord injuries. Established in 2016, the firm operates from its headquarters in Taichung, Taiwan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Wei Liang Huang
- Employees
- 88
- Website
- www.ever-supreme.com.tw
- Address
- TW
Ever Supreme Bio Technology Co., Ltd. (6712) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |

